<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04039919</url>
  </required_header>
  <id_info>
    <org_study_id>UP0071</org_study_id>
    <secondary_id>2019-000703-32</secondary_id>
    <nct_id>NCT04039919</nct_id>
  </id_info>
  <brief_title>A Study to Test the Pharmacodynamic, Pharmacokinetic, Safety, and Tolerability of Padsevonil in Healthy Study Participants Receiving Either Ethanol or Cannabidiol</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Randomized, Single-Center, Cross-Over Study to Investigate the Pharmacodynamic, Pharmacokinetic, Safety, and Tolerability Profiles of Padsevonil in Healthy Study Participants Receiving Either Ethanol or Cannabidiol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the pharmacodynamic (PD) interaction between&#xD;
      steady-steady treatment with padsevonil (PSL) and Ethanol and the pharmacokinetic (PK)&#xD;
      interaction between stead-state treatment with PSL and cannabidiol (CBD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Based on available data, UCB has decided to stop development of padsevonil as adjunctive&#xD;
    treatment of focal-onset seizures&#xD;
  </why_stopped>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Actual">May 22, 2020</completion_date>
  <primary_completion_date type="Actual">May 22, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Smooth Pursuit Eye Movements on Day 1 of Period 1 or Day 3 of Period 2 During Part A</measure>
    <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8 and 10 hours postdose on Day 1 of Period 1 or Day 3 of Period 2</time_frame>
    <description>Smooth pursuit to assess eye movement coordination and attention to evaluate the ethanol effect. The average percentage of smooth pursuit for all stimulus frequencies was used as a parameter. Participants received either ethanol or placebo on Day 1 of Period 1 or on Day 3 of Period 2. Therefore, the results were summarized by treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Smooth Pursuit Eye Movements on Day 5 of Period 4 or Day 7 of Period 5 During Part A</measure>
    <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8 and 10 hours postdose on Day 5 of Period 4 or Day 7 of Period 5</time_frame>
    <description>Smooth pursuit to assess eye movement coordination and attention to evaluate the ethanol effect. The average percentage of smooth pursuit for all stimulus frequencies was used as a parameter. Participants received either ethanol or placebo on Day 5 of Period 4 or Day 7 of Period 5. Therefore, the results were summarized by treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Padsevonil During Part B</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
    <description>Cmax is maximum observed plasma concentration at steady state of padsevonil.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Cannabidiol During Part B</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
    <description>Cmax is maximum observed plasma concentration at steady state of CBD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve Over a Dosing Interval (AUCtau) of Padsevonil During Part B</measure>
    <time_frame>Predose up to 12 hours post dose</time_frame>
    <description>AUCtau is the area under the curve over a dosing interval of padsevonil.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve Over a Dosing Interval (AUCtau) of Cannabidiol During Part B</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
    <description>AUCtau is the area under the curve over a dosing interval of CBD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breath Concentration of Ethanol Over Time on Day 1 of Period 1 or Day 3 of Period 2 During Part A</measure>
    <time_frame>-0.4, -0.3, -0.2, -0.16, -0.08, Predose, 0.16, 0.3, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7 and 8 hours postdose on Day 1 of Period 1 or on Day 3 of Period 2</time_frame>
    <description>Continuous infusion of ethanol began with a 30 minute loading phase (prior to 0 hours) and was continued for 5 hours with adjustments during the infusion. Participants received either ethanol on Day 1 of Period 1 or on Day 3 of Period 2. Therefore, the results were summarized by treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breath Concentration of Ethanol Over Time on Day 5 of Period 4 or Day 7 of Period 5 During Part A</measure>
    <time_frame>-0.4, -0.3, -0.2, -0.16, -0.08, Predose, 0.16, 0.3, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7 and 8 hours postdose on Day 5 of Period 4 or Day 7 of Period 5</time_frame>
    <description>Continuous infusion of ethanol began with a 30 minute loading phase (prior to 0 hours) and was continued for 5 hours with adjustments during the infusion. Participants received either ethanol on Day 5 of Period 4 or Day 7 of Period 5. Therefore, the results were summarized by treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Padsevonil During Part A</measure>
    <time_frame>Predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 12 hours postdose on Day 5</time_frame>
    <description>Cmax,ss is the maximum observed plasma concentration at steady state of padsevonil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve Over a Dosing Interval (AUCtau) of Padsevonil During Part A</measure>
    <time_frame>Predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 12 hours postdose on Day 5</time_frame>
    <description>AUC0-tau is the area under the curve over a dosing interval of padsevonil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2) of Padsevonil During Part B</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
    <description>t1/2 is the apparent terminal half-life of padsevonil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2) of Cannabidiol During Part B</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
    <description>t1/2 is the apparent terminal half-life of CBD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Body Clearance at Steady State (CLss/F) of Padsevonil During Part B</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
    <description>CLss/F is the apparent total body clearance at steady state following extravascular administration of padsevonil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Body Clearance at Steady State (CLss/F) of Cannabidiol During Part B</measure>
    <time_frame>Predose up to 12 hours postdose</time_frame>
    <description>CLss/F is the apparent total body clearance at steady state following extravascular administration of CBD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Smooth Pursuit Eye Movements During Part B</measure>
    <time_frame>Treatment Period 1: Screening, Day 1 and Day 2</time_frame>
    <description>Smooth pursuit to assess eye movement coordination and attention to evaluate the ethanol effect. The average percentage of smooth pursuit for all stimulus frequencies was used as a parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saccadic Peak Velocity to Assess Sedation on Day 1 of Period 1 or Day 3 of Period 2 During Part A</measure>
    <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8 and 10 hours postdose on Day 1 of Period 1 or Day 3 of Period 2</time_frame>
    <description>Sixteen saccades were recorded with interstimulus intervals varying randomly. Average values of latency (reaction time), saccadic peak velocity of all correct saccades, and inaccuracy of all saccades were used as parameters. Participants received either ethanol or placebo on Day 1 of Period 1 or on Day 3 of Period 2. Therefore, the results were summarized by treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saccadic Peak Velocity to Assess Sedation on Day 5 of Period 4 or Day 7 of Period 5 During Part A</measure>
    <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8 and 10 hours postdose on Day 5 of Period 4 or Day 7 of Period 5</time_frame>
    <description>Sixteen saccades were recorded with interstimulus intervals varying randomly. Average values of latency (reaction time), saccadic peak velocity of all correct saccades, and inaccuracy of all saccades were used as parameters. Participants received either ethanol or placebo on Day 5 of Period 4 or Day 7 of Period 5. Therefore, the results were summarized by treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saccadic Peak Velocity to Assess Sedation During Part B</measure>
    <time_frame>Treatment Period 1: Screening, Day 1 and Day 2</time_frame>
    <description>Sixteen saccades were recorded with interstimulus intervals varying randomly. Average values of latency (reaction time), saccadic peak velocity of all correct saccades, and inaccuracy of all saccades were used as parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adaptive Tracking to Assess Visuo-Motor Control and Vigilance on Day 1 of Period 1 or Day 3 of Period 2 During Part A</measure>
    <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8 and 10 hours postdose on Day 1 of Period 1 or Day 3 of Period 2</time_frame>
    <description>The adaptive tracking test was performed as originally described by Borland and Nicholson (Borland and Nicholson, 1984). Performance was scored after a fixed period of 3.5 minutes and reflected visuo-motor control and vigilance. The average performance scores were used in the analysis. Participants received either ethanol or placebo on Day 1 of Period 1 or on Day 3 of Period 2. Therefore, the results were summarized by treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adaptive Tracking to Assess Visuo-Motor Control and Vigilance on Day 5 of Period 4 or Day 7 of Period 5 During Part A</measure>
    <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8 and 10 hours on Day 5 of Period 4 or Day 7 of Period 5</time_frame>
    <description>The adaptive tracking test was performed as originally described by Borland and Nicholson (Borland and Nicholson, 1984). Performance was scored after a fixed period of 3.5 minutes and reflected visuo-motor control and vigilance. The average performance scores were used in the analysis. Participants received either ethanol or placebo on Day 5 of Period 4 or Day 7 of Period 5. Therefore, the results were summarized by treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adaptive Tracking to Assess Visuo-Motor Control and Vigilance During Part B</measure>
    <time_frame>Treatment Period 1: Screening, Day 1 and Day 2</time_frame>
    <description>The adaptive tracking test was performed as originally described by Borland and Nicholson (Borland and Nicholson, 1984). Performance was scored after a fixed period of 3.5 minutes and reflected visuo-motor control and vigilance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Sway to Assess Postural Stability on Day 1 of Period 1 or Day 3 of Period 2 During Part A</measure>
    <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8 and 10 hours postdose on Day 1 of Period 1 or Day 3 of Period 2</time_frame>
    <description>Body Sway test measured the study participant's body movements in a single direction. Body sway was measured by CHCR NeuroCart. Study participants were asked to stand erect and motionless with their eyes closed. The amplitude and direction of any Body Sway was recorded for 1 minute. Participants received either ethanol or placebo on Day 1 of Period 1 or on Day 3 of Period 2. Therefore, the results were summarized by treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Sway to Assess Postural Stability on Day 5 of Period 4 or Day 7 of Period 5 During Part A</measure>
    <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8 and 10 hours on Day 5 of Period 4 or Day 7 of Period 5</time_frame>
    <description>Body Sway test measured the study participant's body movements in a single direction. Body sway was measured by CHCR NeuroCart. Study participants were asked to stand erect and motionless with their eyes closed. The amplitude and direction of any Body Sway was recorded for 1 minute. Participants received either ethanol or placebo on Day 5 of Period 4 or Day 7 of Period 5. Therefore, the results were summarized by treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Sway to Assess Postural Stability During Part B</measure>
    <time_frame>Treatment Period 1: Screening, Day 1 and Day 2</time_frame>
    <description>Body Sway test measured the study participant's body movements in a single direction. Body sway was measured by CHCR NeuroCart. Study participants were asked to stand erect and motionless with their eyes closed. The amplitude and direction of any Body Sway was recorded for 1 minute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events During Part A</measure>
    <time_frame>From Screening up to the Safety Follow-up visit of Part A (up to Day 26)</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant or trial participant that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events During Part B</measure>
    <time_frame>From Screening up to the Safety Follow-up visit of Part B (up to Day 66)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant or trial participant that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events During Part A</measure>
    <time_frame>From Screening up to the Safety Follow-up visit of Part A (up to Day 26)</time_frame>
    <description>A serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, is life-threatening, required in patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, is an infection that requires treatment parenteral antibiotics, other important medical events which based on medical or scientific judgement may jeopardize the participants, or may require medical or surgical intervention to prevent any of the above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events During Part B</measure>
    <time_frame>From Screening up to the Safety Follow-up visit of Part B (up to Day 66)</time_frame>
    <description>A SAE was any untoward medical occurrence that at any dose resulted in death, is life-threatening, required in patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, is an infection that requires treatment parenteral antibiotics, other important medical events which based on medical or scientific judgement may jeopardize the participants, or may require medical or surgical intervention to prevent any of the above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-related Adverse Events During Part A</measure>
    <time_frame>From Baseline up to Safety Follow-up visit of Part A (up to Day 26)</time_frame>
    <description>Treatment-related adverse event was an adverse event for which a causal relationship between the product and the occurrence is suspected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-related Adverse Events During Part B</measure>
    <time_frame>From Baseline up to Safety Follow-up visit of Part B (up to Day 66)</time_frame>
    <description>Treatment-related adverse event was an adverse event for which a causal relationship between the product and the occurrence is suspected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events Leading to Discontinuation of the Study During Part A</measure>
    <time_frame>From Screening up to Safety Follow-up visit of Part A (up to Day 26)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events Leading to Discontinuation of the Study During Part B</measure>
    <time_frame>From Screening up to Safety Follow-up visit of Part B (up to Day 66)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Part A: Padsevonil and Ethanol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive Padsevonil and Ethanol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Padsevonil and Ethanol-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be randomized to receive Padsevonil and Ethanol-Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Ethanol and Ethanol-Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will be randomized to receive Ethanol and Ethanol-Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Ethanol-Placebo and Ethanol</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will be randomized to receive Ethanol and Ethanol-Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Padsevonil and Cannabidiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive Padsevonil and Cannabidiol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Padsevonil-Placebo and Cannabidiol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be randomized to receive Padsevonil-Placebo and Cannabidiol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Padsevonil</intervention_name>
    <description>Padsevonil will be administered in predefined dosages.</description>
    <arm_group_label>Part A: Padsevonil and Ethanol</arm_group_label>
    <arm_group_label>Part A: Padsevonil and Ethanol-Placebo</arm_group_label>
    <arm_group_label>Part B: Padsevonil and Cannabidiol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (PSL)</intervention_name>
    <description>Placebo will be provided matching Padsevonil to maintain the blinding.</description>
    <arm_group_label>Part B: Padsevonil-Placebo and Cannabidiol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be 18 to 55 years of age inclusive, at the time of signing the&#xD;
             informed consent&#xD;
&#xD;
          -  Participants who are overtly healthy as determined by medical evaluation including&#xD;
             medical history, physical examination, laboratory tests, and cardiac monitoring&#xD;
&#xD;
          -  Participant must have previous experience with alcohol consumption and, therefore,&#xD;
             must be familiar with the effects and able to tolerate social amounts of alcohol&#xD;
&#xD;
          -  Participant has a body weight of at least 50 kg (males) or 45 kg (females) and body&#xD;
             mass index (BMI) within the range 18 to 30 kg/m2 (inclusive)&#xD;
&#xD;
          -  Participants are male or female:&#xD;
&#xD;
          -  A male participant must agree to use contraception as detailed in the protocol during&#xD;
             the treatment period and for at least 7 days after the last dose of study treatment&#xD;
             and refrain from donating sperm during this period&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant, not&#xD;
             breastfeeding, and at least 1 of the following conditions applies:&#xD;
&#xD;
          -  Not a woman of childbearing potential (WOCBP) as defined n the protocol OR&#xD;
&#xD;
          -  A WOCBP who agrees to follow the contraceptive guidance in the protocol during the&#xD;
             Treatment Period and for at least 90 days after the last dose of study treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has history or presence of cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrinological, hematological, or neurological disorders capable&#xD;
             of significantly altering the absorption, metabolism, or elimination of drugs;&#xD;
             constituting a risk when taking the study intervention; or interfering with the&#xD;
             interpretation of data&#xD;
&#xD;
          -  Participant has a history of chronic alcohol or drug abuse within the previous 6&#xD;
             months or the presence of drug or alcohol dependency at Screening or Day -1 or tests&#xD;
             positive for alcohol and/or drugs at Screening or Day -1&#xD;
&#xD;
          -  Participant has a known hypersensitivity to any components of the study medication or&#xD;
             comparative drugs (and/or an investigational device) as stated in this protocol&#xD;
&#xD;
          -  Participant has a history of unexplained syncope or a family history of sudden death&#xD;
             due to long QT syndrome&#xD;
&#xD;
          -  Participant has lymphoma, leukemia, or any malignancy within the past 5 years except&#xD;
             for basal cell or squamous epithelial carcinomas of the skin that have been resected&#xD;
             with no evidence of metastatic disease for 3 years&#xD;
&#xD;
          -  Participant has past or intended use of over-the-counter or prescription medication&#xD;
             including herbal medications within 2 weeks or 5 half-lives prior to dosing&#xD;
&#xD;
          -  Participant has used hepatic enzyme-inducing drugs within 2 months prior to dosing&#xD;
&#xD;
          -  Participant has alanine transaminase (ALT), aspartate aminotransferase (AST), or&#xD;
             alkaline phosphatase (ALP) &gt;1.0x upper limit of normal (ULN)&#xD;
&#xD;
          -  Participant has current or chronic history of liver disease or known hepatic or&#xD;
             biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic&#xD;
             gallstones)&#xD;
&#xD;
          -  Participant has any clinically relevant electrocardiogram (ECG) finding at the&#xD;
             Screening Visit or at Baseline&#xD;
&#xD;
          -  Participant has the presence of hepatitis B surface antigen (HBsAg) at Screening or&#xD;
             within 3 months prior to dosing&#xD;
&#xD;
          -  Participant has a positive hepatitis C antibody test result at Screening or within 3&#xD;
             months prior to starting study intervention&#xD;
&#xD;
          -  Participant has a positive human immunodeficiency virus (HIV) antibody test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>001 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Up0071 001</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>July 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <results_first_submitted>May 21, 2021</results_first_submitted>
  <results_first_submitted_qc>May 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 18, 2021</results_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ethanol</keyword>
  <keyword>Cannabidiol</keyword>
  <keyword>Padsevonil</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Due to the small sample size in this trial, Individual Patient Data cannot be adequately anonymized and there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT04039919/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 27, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT04039919/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study started to enroll participants in July 2019 and concluded in May 2020.</recruitment_details>
      <pre_assignment_details>Participant Flow refers to the All Study Participants Set which included all participants who have signed the Informed Consent form (ICF).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A: Treatment Sequence A</title>
          <description>Participants received ethanol 0.6 grams per liter (g/L) intravenous (IV) infusion on Day 1 during Treatment Period 1 (TP1), followed by placebo (for ethanol IV infusion) on Day 1 during TP2, then padsevonil (PSL) oral tablets 100 mg or 200 mg BID on Day 1 to 4 during TP3, PSL 200 mg BID oral tablets + Ethanol IV infusion on Day 5 during TP4, PSL oral tablets 100 mg or 200 mg + Placebo (for ethanol IV infusion) on Day 7 during TP5, and then PSL 100 mg BID oral tablets on Day 9 during TP6. There was a washout of at least 2 days between Treatment Periods 2 and 3.</description>
        </group>
        <group group_id="P2">
          <title>Part A: Treatment Sequence B</title>
          <description>Participants received ethanol 0.6 g/L IV infusion on Day 1 during TP1, followed by placebo (for ethanol IV infusion) on Day 1 during TP2, then PSL oral tablets 100 mg or 200 mg BID on Day 1 to 4 during TP3, PSL oral tablets 100 mg or 200 mg + Placebo (for ethanol IV infusion) on Day 5 during TP4, PSL 200 mg BID oral tablets + Ethanol IV infusion on Day 7 during TP5, and then PSL 100 mg BID oral tablets on Day 9 during TP6. There was a washout of at least 2 days between Treatment Periods 2 and 3.</description>
        </group>
        <group group_id="P3">
          <title>Part A: Treatment Sequence C</title>
          <description>Participants received placebo (for ethanol IV infusion) on Day 1 during TP1, followed by ethanol 0.6 g/L IV infusion on Day 1 during TP2, then PSL oral tablets 100 mg or 200 mg BID on Day 1 to 4 during TP3, PSL 200 mg BID oral tablets + Ethanol IV infusion on Day 5 during TP4, PSL oral tablets 100 mg or 200 mg + Placebo (for ethanol IV infusion) on Day 7 during TP5, and then PSL 100 mg BID oral tablets on Day 9 during TP6. There was a washout of at least 2 days between Treatment Periods 2 and 3.</description>
        </group>
        <group group_id="P4">
          <title>Part A: Treatment Sequence D</title>
          <description>Participants received placebo (for ethanol IV infusion) on Day 1 during TP1, followed by ethanol 0.6 g/L IV infusion on Day 1 during TP2, then PSL oral tablets 100 mg or 200 mg BID on Day 1 to 4 during TP3, PSL oral tablets 100 mg or 200 mg + Placebo (for ethanol IV infusion) on Day 5 during TP4, PSL 200 mg BID oral tablets + Ethanol IV infusion on Day 7 during TP5, and then PSL 100 mg BID oral tablets on Day 9 during TP6. There was a washout of at least 2 days between Treatment Periods 2 and 3.</description>
        </group>
        <group group_id="P5">
          <title>Part B: Cannabidiol (CBD)</title>
          <description>Participants received a single oral dose of CBD 10 milligrams per kilogram (mg/kg) solution, under fasted condition on Day 1 during TP1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor's decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 6</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics refer to Safety Set (SS) which consisted of all study participants who were randomized and had received at least 1 dose (any amount) of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Part A: Treatment Sequence A</title>
          <description>Participants received ethanol 0.6 grams per liter (g/L) intravenous (IV) infusion on Day 1 during Treatment Period 1 (TP1), followed by placebo (for ethanol IV infusion) on Day 1 during TP2, then padsevonil (PSL) oral tablets 100 mg or 200 mg BID on Day 1 to 4 during TP3, PSL 200 mg BID oral tablets + Ethanol IV infusion on Day 5 during TP4, PSL oral tablets 100 mg or 200 mg + Placebo (for ethanol IV infusion) on Day 7 during TP5, and then PSL 100 mg BID oral tablets on Day 9 during TP6. There was a washout of at least 2 days between Treatment Periods 2 and 3.</description>
        </group>
        <group group_id="B2">
          <title>Part A: Treatment Sequence B</title>
          <description>Participants received ethanol 0.6 g/L IV infusion on Day 1 during TP1, followed by placebo (for ethanol IV infusion) on Day 1 during TP2, then PSL oral tablets 100 mg or 200 mg BID on Day 1 to 4 during TP3, PSL oral tablets 100 mg or 200 mg + Placebo (for ethanol IV infusion) on Day 5 during TP4, PSL 200 mg BID oral tablets + Ethanol IV infusion on Day 7 during TP5, and then PSL 100 mg BID oral tablets on Day 9 during TP6. There was a washout of at least 2 days between Treatment Periods 2 and 3.</description>
        </group>
        <group group_id="B3">
          <title>Part A: Treatment Sequence C</title>
          <description>Participants received placebo (for ethanol IV infusion) on Day 1 during TP1, followed by ethanol 0.6 g/L IV infusion on Day 1 during TP2, then PSL oral tablets 100 mg or 200 mg BID on Day 1 to 4 during TP3, PSL 200 mg BID oral tablets + Ethanol IV infusion on Day 5 during TP4, PSL oral tablets 100 mg or 200 mg + Placebo (for ethanol IV infusion) on Day 7 during TP5, and then PSL 100 mg BID oral tablets on Day 9 during TP6. There was a washout of at least 2 days between Treatment Periods 2 and 3.</description>
        </group>
        <group group_id="B4">
          <title>Part A: Treatment Sequence D</title>
          <description>Participants received placebo (for ethanol IV infusion) on Day 1 during TP1, followed by ethanol 0.6 g/L IV infusion on Day 1 during TP2, then PSL oral tablets 100 mg or 200 mg BID on Day 1 to 4 during TP3, PSL oral tablets 100 mg or 200 mg + Placebo (for ethanol IV infusion) on Day 5 during TP4, PSL 200 mg BID oral tablets + Ethanol IV infusion on Day 7 during TP5, and then PSL 100 mg BID oral tablets on Day 9 during TP6. There was a washout of at least 2 days between Treatment Periods 2 and 3.</description>
        </group>
        <group group_id="B5">
          <title>Part B: Cannabidiol (CBD)</title>
          <description>Participants received a single oral dose of CBD 10 milligrams per kilogram (mg/kg) solution, under fasted condition on Day 1 during TP1.</description>
        </group>
        <group group_id="B6">
          <title>Total Title</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="16"/>
            <count group_id="B6" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.3" spread="9.9"/>
                    <measurement group_id="B2" value="30.8" spread="9.1"/>
                    <measurement group_id="B3" value="28.4" spread="7.0"/>
                    <measurement group_id="B4" value="30.7" spread="4.1"/>
                    <measurement group_id="B5" value="27.9" spread="9.3"/>
                    <measurement group_id="B6" value="29.2" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other or Mixed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Smooth Pursuit Eye Movements on Day 1 of Period 1 or Day 3 of Period 2 During Part A</title>
        <description>Smooth pursuit to assess eye movement coordination and attention to evaluate the ethanol effect. The average percentage of smooth pursuit for all stimulus frequencies was used as a parameter. Participants received either ethanol or placebo on Day 1 of Period 1 or on Day 3 of Period 2. Therefore, the results were summarized by treatment.</description>
        <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8 and 10 hours postdose on Day 1 of Period 1 or Day 3 of Period 2</time_frame>
        <population>Full Analysis Set (FAS) consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation. Here, n (number analyzed) signifies participants evaluable at specified time points only.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Ethanol (FAS)</title>
            <description>Participants received ethanol 0.6 g/L IV infusion on Day 1 during TP1 in Treatment Sequence A and B and on Day 1 during TP2 in Treatment Sequence C and D. Participants formed the FAS.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Placebo (FAS)</title>
            <description>Participants received matching placebo (for ethanol IV infusion) on Day 1 during TP1 in Treatment Sequence A and B and on Day 1 during TP2 in Treatment Sequence C and D. Participants formed the Full Analysis Set (FAS).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Smooth Pursuit Eye Movements on Day 1 of Period 1 or Day 3 of Period 2 During Part A</title>
          <description>Smooth pursuit to assess eye movement coordination and attention to evaluate the ethanol effect. The average percentage of smooth pursuit for all stimulus frequencies was used as a parameter. Participants received either ethanol or placebo on Day 1 of Period 1 or on Day 3 of Period 2. Therefore, the results were summarized by treatment.</description>
          <population>Full Analysis Set (FAS) consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation. Here, n (number analyzed) signifies participants evaluable at specified time points only.</population>
          <units>percentage of eye movements</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.838" spread="9.110"/>
                    <measurement group_id="O2" value="43.252" spread="8.688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.046" spread="8.674"/>
                    <measurement group_id="O2" value="43.661" spread="9.345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.604" spread="8.574"/>
                    <measurement group_id="O2" value="43.748" spread="10.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.300" spread="8.778"/>
                    <measurement group_id="O2" value="42.930" spread="9.636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.726" spread="7.441"/>
                    <measurement group_id="O2" value="42.809" spread="10.639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.822" spread="8.405"/>
                    <measurement group_id="O2" value="42.478" spread="9.351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.913" spread="7.359"/>
                    <measurement group_id="O2" value="42.622" spread="9.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.570" spread="9.353"/>
                    <measurement group_id="O2" value="43.300" spread="8.960"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.948" spread="10.245"/>
                    <measurement group_id="O2" value="44.026" spread="10.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.491" spread="8.928"/>
                    <measurement group_id="O2" value="43.504" spread="11.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Smooth Pursuit Eye Movements on Day 5 of Period 4 or Day 7 of Period 5 During Part A</title>
        <description>Smooth pursuit to assess eye movement coordination and attention to evaluate the ethanol effect. The average percentage of smooth pursuit for all stimulus frequencies was used as a parameter. Participants received either ethanol or placebo on Day 5 of Period 4 or Day 7 of Period 5. Therefore, the results were summarized by treatment.</description>
        <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8 and 10 hours postdose on Day 5 of Period 4 or Day 7 of Period 5</time_frame>
        <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation. Here, Number of participants analyzed signifies participants who were evaluable for the assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: PSL + Ethanol (FAS)</title>
            <description>Participants received PSL 200 mg BID oral tablets + Ethanol IV infusion on Day 5 during TP4 in Treatment Sequence A and C and on Day 7 during TP5 in Treatment Sequence B and D. Participants formed the FAS.</description>
          </group>
          <group group_id="O2">
            <title>Part A: PSL + Placebo (FAS)</title>
            <description>Participants received PSL oral tablets 100 mg or 200 mg + Placebo (for ethanol IV infusion) on Day 7 during TP5 in Treatment Sequence A and C and on Day 5 during TP4 in Treatment Sequence B and D. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Smooth Pursuit Eye Movements on Day 5 of Period 4 or Day 7 of Period 5 During Part A</title>
          <description>Smooth pursuit to assess eye movement coordination and attention to evaluate the ethanol effect. The average percentage of smooth pursuit for all stimulus frequencies was used as a parameter. Participants received either ethanol or placebo on Day 5 of Period 4 or Day 7 of Period 5. Therefore, the results were summarized by treatment.</description>
          <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation. Here, Number of participants analyzed signifies participants who were evaluable for the assessment.</population>
          <units>percentage of eye movements</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.107" spread="9.930"/>
                    <measurement group_id="O2" value="41.402" spread="8.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.591" spread="7.140"/>
                    <measurement group_id="O2" value="39.655" spread="9.703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.874" spread="6.790"/>
                    <measurement group_id="O2" value="35.814" spread="7.893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.309" spread="5.321"/>
                    <measurement group_id="O2" value="36.036" spread="9.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.530" spread="6.881"/>
                    <measurement group_id="O2" value="36.727" spread="9.512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.400" spread="9.466"/>
                    <measurement group_id="O2" value="36.668" spread="8.411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.239" spread="6.750"/>
                    <measurement group_id="O2" value="35.714" spread="8.865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.761" spread="8.383"/>
                    <measurement group_id="O2" value="38.945" spread="9.676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.604" spread="8.894"/>
                    <measurement group_id="O2" value="37.973" spread="8.849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.570" spread="10.683"/>
                    <measurement group_id="O2" value="38.591" spread="9.508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Padsevonil During Part B</title>
        <description>Cmax is maximum observed plasma concentration at steady state of padsevonil.</description>
        <time_frame>Predose up to 12 hours postdose</time_frame>
        <population>Analysis of this outcome measure was not performed because the study was terminated. At that time, Part A had been completed, and 16 study participants had been treated with CBD in Treatment Period 1 of Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: PSL</title>
            <description>Zero participants received PSL during Part B because the study was terminated.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Padsevonil During Part B</title>
          <description>Cmax is maximum observed plasma concentration at steady state of padsevonil.</description>
          <population>Analysis of this outcome measure was not performed because the study was terminated. At that time, Part A had been completed, and 16 study participants had been treated with CBD in Treatment Period 1 of Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Cannabidiol During Part B</title>
        <description>Cmax is maximum observed plasma concentration at steady state of CBD.</description>
        <time_frame>Predose up to 12 hours postdose</time_frame>
        <population>Pharmacokinetic Set (PKS) included all study participants that received at least one dose of active study drug and have at least one observable pharmacokinetic measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: CBD (PKS)</title>
            <description>Participants received a single oral dose of CBD 10 mg/kg solution, under fasted condition on Day 1 during TP1. Participants formed the PKS.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Cannabidiol During Part B</title>
          <description>Cmax is maximum observed plasma concentration at steady state of CBD.</description>
          <population>Pharmacokinetic Set (PKS) included all study participants that received at least one dose of active study drug and have at least one observable pharmacokinetic measurement.</population>
          <units>nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Analysis of this outcome measure was not performed because the study was terminated. At that time, Part A had been completed, and 16 study participants had been treated with CBD in Treatment Period 1 of Part B.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve Over a Dosing Interval (AUCtau) of Padsevonil During Part B</title>
        <description>AUCtau is the area under the curve over a dosing interval of padsevonil.</description>
        <time_frame>Predose up to 12 hours post dose</time_frame>
        <population>Analysis of this outcome measure was not performed because the study was terminated. At that time, Part A had been completed, and 16 study participants had been treated with CBD in Treatment Period 1 of Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: PSL</title>
            <description>Zero participants received PSL during Part B because the study was terminated.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve Over a Dosing Interval (AUCtau) of Padsevonil During Part B</title>
          <description>AUCtau is the area under the curve over a dosing interval of padsevonil.</description>
          <population>Analysis of this outcome measure was not performed because the study was terminated. At that time, Part A had been completed, and 16 study participants had been treated with CBD in Treatment Period 1 of Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve Over a Dosing Interval (AUCtau) of Cannabidiol During Part B</title>
        <description>AUCtau is the area under the curve over a dosing interval of CBD.</description>
        <time_frame>Predose up to 12 hours postdose</time_frame>
        <population>PKS included all study participants that received at least one dose of active study drug and have at least one observable pharmacokinetic measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: CBD (PKS)</title>
            <description>Participants received a single oral dose of CBD 10 mg/kg solution, under fasted condition on Day 1 during TP1. Participants formed the PKS.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve Over a Dosing Interval (AUCtau) of Cannabidiol During Part B</title>
          <description>AUCtau is the area under the curve over a dosing interval of CBD.</description>
          <population>PKS included all study participants that received at least one dose of active study drug and have at least one observable pharmacokinetic measurement.</population>
          <units>hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Analysis of this outcome measure was not performed because the study was terminated. At that time, Part A had been completed, and 16 study participants had been treated with CBD in Treatment Period 1 of Part B.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Breath Concentration of Ethanol Over Time on Day 1 of Period 1 or Day 3 of Period 2 During Part A</title>
        <description>Continuous infusion of ethanol began with a 30 minute loading phase (prior to 0 hours) and was continued for 5 hours with adjustments during the infusion. Participants received either ethanol on Day 1 of Period 1 or on Day 3 of Period 2. Therefore, the results were summarized by treatment.</description>
        <time_frame>-0.4, -0.3, -0.2, -0.16, -0.08, Predose, 0.16, 0.3, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7 and 8 hours postdose on Day 1 of Period 1 or on Day 3 of Period 2</time_frame>
        <population>PKS included all study participants that received at least one dose of active study drug and have at least one observable pharmacokinetic measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Ethanol (PKS)</title>
            <description>Participants received ethanol 0.6 g/L IV infusion on Day 1 during TP1 in Treatment Sequence A and B and on Day 1 during TP2 in Treatment Sequence C and D. Participants formed the Pharmacokinetic Set (PKS).</description>
          </group>
        </group_list>
        <measure>
          <title>Breath Concentration of Ethanol Over Time on Day 1 of Period 1 or Day 3 of Period 2 During Part A</title>
          <description>Continuous infusion of ethanol began with a 30 minute loading phase (prior to 0 hours) and was continued for 5 hours with adjustments during the infusion. Participants received either ethanol on Day 1 of Period 1 or on Day 3 of Period 2. Therefore, the results were summarized by treatment.</description>
          <population>PKS included all study participants that received at least one dose of active study drug and have at least one observable pharmacokinetic measurement.</population>
          <units>grams per liter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>-0.4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.290" lower_limit="0.254" upper_limit="0.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-0.3 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.428" lower_limit="0.379" upper_limit="0.483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-0.2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.477" lower_limit="0.446" upper_limit="0.511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-0.16 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.530" lower_limit="0.499" upper_limit="0.564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-0.08 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.562" lower_limit="0.539" upper_limit="0.585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.555" lower_limit="0.538" upper_limit="0.571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.16 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.578" lower_limit="0.558" upper_limit="0.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.3 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.592" lower_limit="0.574" upper_limit="0.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.574" lower_limit="0.552" upper_limit="0.598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.552" lower_limit="0.525" upper_limit="0.581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.557" lower_limit="0.533" upper_limit="0.583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.568" lower_limit="0.544" upper_limit="0.593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.574" lower_limit="0.547" upper_limit="0.601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.572" lower_limit="0.544" upper_limit="0.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.574" lower_limit="0.556" upper_limit="0.593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.593" lower_limit="0.575" upper_limit="0.612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4.5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.603" lower_limit="0.583" upper_limit="0.624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.590" lower_limit="0.575" upper_limit="0.605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.356" lower_limit="0.322" upper_limit="0.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.172" lower_limit="0.139" upper_limit="0.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.105" lower_limit="0.073" upper_limit="0.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Breath Concentration of Ethanol Over Time on Day 5 of Period 4 or Day 7 of Period 5 During Part A</title>
        <description>Continuous infusion of ethanol began with a 30 minute loading phase (prior to 0 hours) and was continued for 5 hours with adjustments during the infusion. Participants received either ethanol on Day 5 of Period 4 or Day 7 of Period 5. Therefore, the results were summarized by treatment.</description>
        <time_frame>-0.4, -0.3, -0.2, -0.16, -0.08, Predose, 0.16, 0.3, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7 and 8 hours postdose on Day 5 of Period 4 or Day 7 of Period 5</time_frame>
        <population>PKS included all study participants that received at least one dose of active study drug and have at least one observable pharmacokinetic measurement. Here, n (number analyzed) signifies participants evaluable at specified time points only.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: PSL + Ethanol (PKS)</title>
            <description>Participants received PSL 200 mg BID oral tablets + Ethanol IV infusion on Day 5 during TP4 in Treatment Sequence A and C and on Day 7 during TP5 in Treatment Sequence B and D. Participants formed the PKS.</description>
          </group>
        </group_list>
        <measure>
          <title>Breath Concentration of Ethanol Over Time on Day 5 of Period 4 or Day 7 of Period 5 During Part A</title>
          <description>Continuous infusion of ethanol began with a 30 minute loading phase (prior to 0 hours) and was continued for 5 hours with adjustments during the infusion. Participants received either ethanol on Day 5 of Period 4 or Day 7 of Period 5. Therefore, the results were summarized by treatment.</description>
          <population>PKS included all study participants that received at least one dose of active study drug and have at least one observable pharmacokinetic measurement. Here, n (number analyzed) signifies participants evaluable at specified time points only.</population>
          <units>grams per liter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>-0.4 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.321" lower_limit="0.281" upper_limit="0.367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-0.3 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.464" lower_limit="0.417" upper_limit="0.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-0.2 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.499" lower_limit="0.451" upper_limit="0.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-0.16 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.524" lower_limit="0.492" upper_limit="0.558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-0.08 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.505" lower_limit="0.468" upper_limit="0.545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.499" lower_limit="0.467" upper_limit="0.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.16 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.591" lower_limit="0.567" upper_limit="0.617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.3 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.622" lower_limit="0.606" upper_limit="0.639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.608" lower_limit="0.591" upper_limit="0.624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.581" lower_limit="0.560" upper_limit="0.603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.566" lower_limit="0.544" upper_limit="0.588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.566" lower_limit="0.540" upper_limit="0.593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.579" lower_limit="0.550" upper_limit="0.608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.608" lower_limit="0.585" upper_limit="0.631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.602" lower_limit="0.582" upper_limit="0.623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.612" lower_limit="0.593" upper_limit="0.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.610" lower_limit="0.590" upper_limit="0.631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.613" lower_limit="0.590" upper_limit="0.637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.373" lower_limit="0.338" upper_limit="0.411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.199" lower_limit="0.171" upper_limit="0.232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.084" lower_limit="0.066" upper_limit="0.108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Padsevonil During Part A</title>
        <description>Cmax,ss is the maximum observed plasma concentration at steady state of padsevonil.</description>
        <time_frame>Predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 12 hours postdose on Day 5</time_frame>
        <population>PKS included all study participants that received at least one dose of active study drug and have at least one observable pharmacokinetic measurement. Here, Number of participants analyzed signifies participants who were evaluable for the assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: PSL + Ethanol (PKS)</title>
            <description>Participants received PSL 200 mg BID oral tablets + Ethanol IV infusion on Day 5 during TP4 in Treatment Sequence A and C and on Day 7 during TP5 in Treatment Sequence B and D. Participants formed the PKS.</description>
          </group>
          <group group_id="O2">
            <title>Part A: PSL + Placebo (PKS)</title>
            <description>Participants received PSL oral tablets 100 mg or 200 mg + Placebo (for ethanol IV infusion) on Day 7 during TP5 in Treatment Sequence A and C and on Day 5 during TP4 in Treatment Sequence B and D. Participants formed the PKS.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of Padsevonil During Part A</title>
          <description>Cmax,ss is the maximum observed plasma concentration at steady state of padsevonil.</description>
          <population>PKS included all study participants that received at least one dose of active study drug and have at least one observable pharmacokinetic measurement. Here, Number of participants analyzed signifies participants who were evaluable for the assessment.</population>
          <units>nanograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="832.9" lower_limit="488.3" upper_limit="1421"/>
                    <measurement group_id="O2" value="1077" lower_limit="778.6" upper_limit="1489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The log-transformed PK parameters was analyzed by a mixed analysis of variance (ANOVA) with period and treatment as fixed effects and study participant as the random effect. The estimates and confidence intervals are back-transformed after the analysis.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric LS Mean ratio</param_type>
            <param_value>0.7850</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6513</ci_lower_limit>
            <ci_upper_limit>0.9461</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve Over a Dosing Interval (AUCtau) of Padsevonil During Part A</title>
        <description>AUC0-tau is the area under the curve over a dosing interval of padsevonil.</description>
        <time_frame>Predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 12 hours postdose on Day 5</time_frame>
        <population>PKS included all study participants that received at least one dose of active study drug and have at least one observable pharmacokinetic measurement. Here, Number of participants analyzed signifies participants who were evaluable for the assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: PSL + Ethanol (PKS)</title>
            <description>Participants received PSL 200 mg BID oral tablets + Ethanol IV infusion on Day 5 during TP4 in Treatment Sequence A and C and on Day 7 during TP5 in Treatment Sequence B and D. Participants formed the PKS.</description>
          </group>
          <group group_id="O2">
            <title>Part A: PSL + Placebo (PKS)</title>
            <description>Participants received PSL oral tablets 100 mg or 200 mg + Placebo (for ethanol IV infusion) on Day 7 during TP5 in Treatment Sequence A and C and on Day 5 during TP4 in Treatment Sequence B and D. Participants formed the PKS.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve Over a Dosing Interval (AUCtau) of Padsevonil During Part A</title>
          <description>AUC0-tau is the area under the curve over a dosing interval of padsevonil.</description>
          <population>PKS included all study participants that received at least one dose of active study drug and have at least one observable pharmacokinetic measurement. Here, Number of participants analyzed signifies participants who were evaluable for the assessment.</population>
          <units>hours*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3504" lower_limit="2010" upper_limit="6109"/>
                    <measurement group_id="O2" value="4289" lower_limit="2904" upper_limit="6335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The log-transformed PK parameters was analyzed by a mixed ANOVA with period and treatment as fixed effects and study participant as the random effect. The estimates and confidence intervals are back-transformed after the analysis.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric LS Mean Ratio</param_type>
            <param_value>0.8342</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6999</ci_lower_limit>
            <ci_upper_limit>0.9942</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life (t1/2) of Padsevonil During Part B</title>
        <description>t1/2 is the apparent terminal half-life of padsevonil.</description>
        <time_frame>Predose up to 12 hours postdose</time_frame>
        <population>Analysis of this outcome measure was not performed because the study was terminated. At that time, Part A had been completed, and 16 study participants had been treated with CBD in Treatment Period 1 of Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: PSL</title>
            <description>Zero participants received PSL during Part B because the study was terminated.</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life (t1/2) of Padsevonil During Part B</title>
          <description>t1/2 is the apparent terminal half-life of padsevonil.</description>
          <population>Analysis of this outcome measure was not performed because the study was terminated. At that time, Part A had been completed, and 16 study participants had been treated with CBD in Treatment Period 1 of Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life (t1/2) of Cannabidiol During Part B</title>
        <description>t1/2 is the apparent terminal half-life of CBD.</description>
        <time_frame>Predose up to 12 hours postdose</time_frame>
        <population>PKS included all study participants that received at least one dose of active study drug and have at least one observable pharmacokinetic measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: CBD (PKS)</title>
            <description>Participants received a single oral dose of CBD 10 mg/kg solution, under fasted condition on Day 1 during TP1. Participants formed the PKS.</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life (t1/2) of Cannabidiol During Part B</title>
          <description>t1/2 is the apparent terminal half-life of CBD.</description>
          <population>PKS included all study participants that received at least one dose of active study drug and have at least one observable pharmacokinetic measurement.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Analysis of this outcome measure was not performed because the study was terminated. At that time, Part A had been completed, and 16 study participants had been treated with CBD in Treatment Period 1 of Part B.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Total Body Clearance at Steady State (CLss/F) of Padsevonil During Part B</title>
        <description>CLss/F is the apparent total body clearance at steady state following extravascular administration of padsevonil.</description>
        <time_frame>Predose up to 12 hours postdose</time_frame>
        <population>Analysis of this outcome measure was not performed because the study was terminated. At that time, Part A had been completed, and 16 study participants had been treated with CBD in Treatment Period 1 of Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: PSL</title>
            <description>Zero participants received PSL during Part B because the study was terminated.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Body Clearance at Steady State (CLss/F) of Padsevonil During Part B</title>
          <description>CLss/F is the apparent total body clearance at steady state following extravascular administration of padsevonil.</description>
          <population>Analysis of this outcome measure was not performed because the study was terminated. At that time, Part A had been completed, and 16 study participants had been treated with CBD in Treatment Period 1 of Part B.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Total Body Clearance at Steady State (CLss/F) of Cannabidiol During Part B</title>
        <description>CLss/F is the apparent total body clearance at steady state following extravascular administration of CBD.</description>
        <time_frame>Predose up to 12 hours postdose</time_frame>
        <population>PKS included all study participants that received at least one dose of active study drug and have at least one observable pharmacokinetic measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: CBD (PKS)</title>
            <description>Participants received a single oral dose of CBD 10 mg/kg solution, under fasted condition on Day 1 during TP1. Participants formed the PKS.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Body Clearance at Steady State (CLss/F) of Cannabidiol During Part B</title>
          <description>CLss/F is the apparent total body clearance at steady state following extravascular administration of CBD.</description>
          <population>PKS included all study participants that received at least one dose of active study drug and have at least one observable pharmacokinetic measurement.</population>
          <units>liter per hour</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Analysis of this outcome measure was not performed because the study was terminated. At that time, Part A had been completed, and 16 study participants had been treated with CBD in Treatment Period 1 of Part B.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Smooth Pursuit Eye Movements During Part B</title>
        <description>Smooth pursuit to assess eye movement coordination and attention to evaluate the ethanol effect. The average percentage of smooth pursuit for all stimulus frequencies was used as a parameter.</description>
        <time_frame>Treatment Period 1: Screening, Day 1 and Day 2</time_frame>
        <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: CBD (FAS)</title>
            <description>Participants received a single oral dose of CBD 10 mg/kg solution, under fasted condition on Day 1 during TP1. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Smooth Pursuit Eye Movements During Part B</title>
          <description>Smooth pursuit to assess eye movement coordination and attention to evaluate the ethanol effect. The average percentage of smooth pursuit for all stimulus frequencies was used as a parameter.</description>
          <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation.</population>
          <units>percentage of eye movements</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Analysis of this outcome measure was not performed because the study was terminated. At that time, Part A had been completed, and 16 study participants had been treated with CBD in Treatment Period 1 of Part B.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saccadic Peak Velocity to Assess Sedation on Day 1 of Period 1 or Day 3 of Period 2 During Part A</title>
        <description>Sixteen saccades were recorded with interstimulus intervals varying randomly. Average values of latency (reaction time), saccadic peak velocity of all correct saccades, and inaccuracy of all saccades were used as parameters. Participants received either ethanol or placebo on Day 1 of Period 1 or on Day 3 of Period 2. Therefore, the results were summarized by treatment.</description>
        <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8 and 10 hours postdose on Day 1 of Period 1 or Day 3 of Period 2</time_frame>
        <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation. Here, n (number analyzed) signifies participants evaluable at specified time points only.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Ethanol (FAS)</title>
            <description>Participants received ethanol 0.6 g/L IV infusion on Day 1 during TP1 in Treatment Sequence A and B and on Day 1 during TP2 in Treatment Sequence C and D. Participants formed the FAS.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Placebo (FAS)</title>
            <description>Participants received matching placebo (for ethanol IV infusion) on Day 1 during TP1 in Treatment Sequence A and B and on Day 1 during TP2 in Treatment Sequence C and D. Participants formed the Full Analysis Set (FAS).</description>
          </group>
        </group_list>
        <measure>
          <title>Saccadic Peak Velocity to Assess Sedation on Day 1 of Period 1 or Day 3 of Period 2 During Part A</title>
          <description>Sixteen saccades were recorded with interstimulus intervals varying randomly. Average values of latency (reaction time), saccadic peak velocity of all correct saccades, and inaccuracy of all saccades were used as parameters. Participants received either ethanol or placebo on Day 1 of Period 1 or on Day 3 of Period 2. Therefore, the results were summarized by treatment.</description>
          <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation. Here, n (number analyzed) signifies participants evaluable at specified time points only.</population>
          <units>degrees per second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="497.873" spread="36.988"/>
                    <measurement group_id="O2" value="502.917" spread="32.543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="471.465" spread="37.890"/>
                    <measurement group_id="O2" value="502.427" spread="47.354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="458.726" spread="34.284"/>
                    <measurement group_id="O2" value="488.761" spread="35.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="455.138" spread="34.045"/>
                    <measurement group_id="O2" value="484.243" spread="37.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="455.445" spread="43.890"/>
                    <measurement group_id="O2" value="479.852" spread="33.906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="459.700" spread="54.621"/>
                    <measurement group_id="O2" value="468.029" spread="36.669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="447.909" spread="29.508"/>
                    <measurement group_id="O2" value="484.778" spread="32.631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="466.417" spread="37.985"/>
                    <measurement group_id="O2" value="479.150" spread="37.994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="474.283" spread="33.625"/>
                    <measurement group_id="O2" value="486.883" spread="38.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="484.513" spread="33.232"/>
                    <measurement group_id="O2" value="489.495" spread="38.495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saccadic Peak Velocity to Assess Sedation on Day 5 of Period 4 or Day 7 of Period 5 During Part A</title>
        <description>Sixteen saccades were recorded with interstimulus intervals varying randomly. Average values of latency (reaction time), saccadic peak velocity of all correct saccades, and inaccuracy of all saccades were used as parameters. Participants received either ethanol or placebo on Day 5 of Period 4 or Day 7 of Period 5. Therefore, the results were summarized by treatment.</description>
        <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8 and 10 hours postdose on Day 5 of Period 4 or Day 7 of Period 5</time_frame>
        <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation. Here, n (number analyzed) signifies participants evaluable at specified time points only.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: PSL + Ethanol (FAS)</title>
            <description>Participants received PSL 200 mg BID oral tablets + Ethanol IV infusion on Day 5 during TP4 in Treatment Sequence A and C and on Day 7 during TP5 in Treatment Sequence B and D. Participants formed the FAS.</description>
          </group>
          <group group_id="O2">
            <title>Part A: PSL + Placebo (FAS)</title>
            <description>Participants received PSL oral tablets 100 mg or 200 mg + Placebo (for ethanol IV infusion) on Day 7 during TP5 in Treatment Sequence A and C and on Day 5 during TP4 in Treatment Sequence B and D. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>Saccadic Peak Velocity to Assess Sedation on Day 5 of Period 4 or Day 7 of Period 5 During Part A</title>
          <description>Sixteen saccades were recorded with interstimulus intervals varying randomly. Average values of latency (reaction time), saccadic peak velocity of all correct saccades, and inaccuracy of all saccades were used as parameters. Participants received either ethanol or placebo on Day 5 of Period 4 or Day 7 of Period 5. Therefore, the results were summarized by treatment.</description>
          <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation. Here, n (number analyzed) signifies participants evaluable at specified time points only.</population>
          <units>degrees per second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="481.335" spread="40.894"/>
                    <measurement group_id="O2" value="466.509" spread="43.334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="434.465" spread="48.160"/>
                    <measurement group_id="O2" value="454.980" spread="35.882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405.517" spread="50.706"/>
                    <measurement group_id="O2" value="427.505" spread="42.232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414.268" spread="61.752"/>
                    <measurement group_id="O2" value="418.748" spread="49.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="401.548" spread="46.004"/>
                    <measurement group_id="O2" value="423.543" spread="51.720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410.386" spread="47.324"/>
                    <measurement group_id="O2" value="442.152" spread="46.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="418.252" spread="41.277"/>
                    <measurement group_id="O2" value="450.319" spread="38.954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="436.268" spread="55.152"/>
                    <measurement group_id="O2" value="470.576" spread="47.370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="480.891" spread="41.106"/>
                    <measurement group_id="O2" value="467.162" spread="37.902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="474.209" spread="41.119"/>
                    <measurement group_id="O2" value="466.933" spread="43.241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saccadic Peak Velocity to Assess Sedation During Part B</title>
        <description>Sixteen saccades were recorded with interstimulus intervals varying randomly. Average values of latency (reaction time), saccadic peak velocity of all correct saccades, and inaccuracy of all saccades were used as parameters.</description>
        <time_frame>Treatment Period 1: Screening, Day 1 and Day 2</time_frame>
        <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: CBD (FAS)</title>
            <description>Participants received a single oral dose of CBD 10 mg/kg solution, under fasted condition on Day 1 during TP1. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>Saccadic Peak Velocity to Assess Sedation During Part B</title>
          <description>Sixteen saccades were recorded with interstimulus intervals varying randomly. Average values of latency (reaction time), saccadic peak velocity of all correct saccades, and inaccuracy of all saccades were used as parameters.</description>
          <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation.</population>
          <units>degrees per second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Analysis of this outcome measure was not performed because the study was terminated. At that time, Part A had been completed, and 16 study participants had been treated with CBD in Treatment Period 1 of Part B.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adaptive Tracking to Assess Visuo-Motor Control and Vigilance on Day 1 of Period 1 or Day 3 of Period 2 During Part A</title>
        <description>The adaptive tracking test was performed as originally described by Borland and Nicholson (Borland and Nicholson, 1984). Performance was scored after a fixed period of 3.5 minutes and reflected visuo-motor control and vigilance. The average performance scores were used in the analysis. Participants received either ethanol or placebo on Day 1 of Period 1 or on Day 3 of Period 2. Therefore, the results were summarized by treatment.</description>
        <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8 and 10 hours postdose on Day 1 of Period 1 or Day 3 of Period 2</time_frame>
        <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation. Here, n (number analyzed) signifies participants evaluable at specified time points only.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Ethanol (FAS)</title>
            <description>Participants received ethanol 0.6 g/L IV infusion on Day 1 during TP1 in Treatment Sequence A and B and on Day 1 during TP2 in Treatment Sequence C and D. Participants formed the FAS.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Placebo (FAS)</title>
            <description>Participants received matching placebo (for ethanol IV infusion) on Day 1 during TP1 in Treatment Sequence A and B and on Day 1 during TP2 in Treatment Sequence C and D. Participants formed the Full Analysis Set (FAS).</description>
          </group>
        </group_list>
        <measure>
          <title>Adaptive Tracking to Assess Visuo-Motor Control and Vigilance on Day 1 of Period 1 or Day 3 of Period 2 During Part A</title>
          <description>The adaptive tracking test was performed as originally described by Borland and Nicholson (Borland and Nicholson, 1984). Performance was scored after a fixed period of 3.5 minutes and reflected visuo-motor control and vigilance. The average performance scores were used in the analysis. Participants received either ethanol or placebo on Day 1 of Period 1 or on Day 3 of Period 2. Therefore, the results were summarized by treatment.</description>
          <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation. Here, n (number analyzed) signifies participants evaluable at specified time points only.</population>
          <units>percentage of time correctly tracked</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3704" spread="5.5709"/>
                    <measurement group_id="O2" value="32.0037" spread="5.6751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0825" spread="4.8924"/>
                    <measurement group_id="O2" value="32.0770" spread="5.7220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7825" spread="5.0093"/>
                    <measurement group_id="O2" value="32.0530" spread="5.6913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6325" spread="4.6875"/>
                    <measurement group_id="O2" value="32.6526" spread="5.5194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5765" spread="5.9118"/>
                    <measurement group_id="O2" value="32.3087" spread="6.0354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4087" spread="6.5784"/>
                    <measurement group_id="O2" value="31.8835" spread="6.0274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9500" spread="5.1829"/>
                    <measurement group_id="O2" value="32.0752" spread="5.8386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9587" spread="5.6291"/>
                    <measurement group_id="O2" value="32.0757" spread="5.6722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0778" spread="5.7553"/>
                    <measurement group_id="O2" value="32.0300" spread="5.8507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5391" spread="5.2327"/>
                    <measurement group_id="O2" value="33.3322" spread="5.9769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adaptive Tracking to Assess Visuo-Motor Control and Vigilance on Day 5 of Period 4 or Day 7 of Period 5 During Part A</title>
        <description>The adaptive tracking test was performed as originally described by Borland and Nicholson (Borland and Nicholson, 1984). Performance was scored after a fixed period of 3.5 minutes and reflected visuo-motor control and vigilance. The average performance scores were used in the analysis. Participants received either ethanol or placebo on Day 5 of Period 4 or Day 7 of Period 5. Therefore, the results were summarized by treatment.</description>
        <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8 and 10 hours on Day 5 of Period 4 or Day 7 of Period 5</time_frame>
        <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation. Here, Number of participants analyzed signifies participants who were evaluable for the assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: PSL + Ethanol (FAS)</title>
            <description>Participants received PSL 200 mg BID oral tablets + Ethanol IV infusion on Day 5 during TP4 in Treatment Sequence A and C and on Day 7 during TP5 in Treatment Sequence B and D. Participants formed the FAS.</description>
          </group>
          <group group_id="O2">
            <title>Part A: PSL + Placebo (FAS)</title>
            <description>Participants received PSL oral tablets 100 mg or 200 mg + Placebo (for ethanol IV infusion) on Day 7 during TP5 in Treatment Sequence A and C and on Day 5 during TP4 in Treatment Sequence B and D. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>Adaptive Tracking to Assess Visuo-Motor Control and Vigilance on Day 5 of Period 4 or Day 7 of Period 5 During Part A</title>
          <description>The adaptive tracking test was performed as originally described by Borland and Nicholson (Borland and Nicholson, 1984). Performance was scored after a fixed period of 3.5 minutes and reflected visuo-motor control and vigilance. The average performance scores were used in the analysis. Participants received either ethanol or placebo on Day 5 of Period 4 or Day 7 of Period 5. Therefore, the results were summarized by treatment.</description>
          <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation. Here, Number of participants analyzed signifies participants who were evaluable for the assessment.</population>
          <units>percentage of time correctly tracked</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5017" spread="7.0354"/>
                    <measurement group_id="O2" value="29.0691" spread="7.1405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3339" spread="6.4727"/>
                    <measurement group_id="O2" value="25.8650" spread="7.7624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4317" spread="7.5471"/>
                    <measurement group_id="O2" value="20.5714" spread="7.7253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1617" spread="6.8895"/>
                    <measurement group_id="O2" value="19.3395" spread="7.8659"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4870" spread="6.9150"/>
                    <measurement group_id="O2" value="25.0859" spread="7.2415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8713" spread="7.9952"/>
                    <measurement group_id="O2" value="27.5827" spread="6.8106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4422" spread="8.3476"/>
                    <measurement group_id="O2" value="29.4377" spread="6.5829"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3652" spread="6.5759"/>
                    <measurement group_id="O2" value="30.3214" spread="6.4549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3570" spread="6.3134"/>
                    <measurement group_id="O2" value="31.3282" spread="5.9957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.6039" spread="6.5557"/>
                    <measurement group_id="O2" value="31.9223" spread="7.1749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adaptive Tracking to Assess Visuo-Motor Control and Vigilance During Part B</title>
        <description>The adaptive tracking test was performed as originally described by Borland and Nicholson (Borland and Nicholson, 1984). Performance was scored after a fixed period of 3.5 minutes and reflected visuo-motor control and vigilance.</description>
        <time_frame>Treatment Period 1: Screening, Day 1 and Day 2</time_frame>
        <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: CBD (FAS)</title>
            <description>Participants received a single oral dose of CBD 10 mg/kg solution, under fasted condition on Day 1 during TP1. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>Adaptive Tracking to Assess Visuo-Motor Control and Vigilance During Part B</title>
          <description>The adaptive tracking test was performed as originally described by Borland and Nicholson (Borland and Nicholson, 1984). Performance was scored after a fixed period of 3.5 minutes and reflected visuo-motor control and vigilance.</description>
          <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation.</population>
          <units>percentage of time correctly tracked</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Analysis of this outcome measure was not performed because the study was terminated. At that time, Part A had been completed, and 16 study participants had been treated with CBD in Treatment Period 1 of Part B.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Sway to Assess Postural Stability on Day 1 of Period 1 or Day 3 of Period 2 During Part A</title>
        <description>Body Sway test measured the study participant's body movements in a single direction. Body sway was measured by CHCR NeuroCart. Study participants were asked to stand erect and motionless with their eyes closed. The amplitude and direction of any Body Sway was recorded for 1 minute. Participants received either ethanol or placebo on Day 1 of Period 1 or on Day 3 of Period 2. Therefore, the results were summarized by treatment.</description>
        <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8 and 10 hours postdose on Day 1 of Period 1 or Day 3 of Period 2</time_frame>
        <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation. Here, n (number analyzed) signifies participants evaluable at specified time points only.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Ethanol (FAS)</title>
            <description>Participants received ethanol 0.6 g/L IV infusion on Day 1 during TP1 in Treatment Sequence A and B and on Day 1 during TP2 in Treatment Sequence C and D. Participants formed the FAS.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Placebo (FAS)</title>
            <description>Participants received matching placebo (for ethanol IV infusion) on Day 1 during TP1 in Treatment Sequence A and B and on Day 1 during TP2 in Treatment Sequence C and D. Participants formed the Full Analysis Set (FAS).</description>
          </group>
        </group_list>
        <measure>
          <title>Body Sway to Assess Postural Stability on Day 1 of Period 1 or Day 3 of Period 2 During Part A</title>
          <description>Body Sway test measured the study participant's body movements in a single direction. Body sway was measured by CHCR NeuroCart. Study participants were asked to stand erect and motionless with their eyes closed. The amplitude and direction of any Body Sway was recorded for 1 minute. Participants received either ethanol or placebo on Day 1 of Period 1 or on Day 3 of Period 2. Therefore, the results were summarized by treatment.</description>
          <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation. Here, n (number analyzed) signifies participants evaluable at specified time points only.</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234.258" spread="131.198"/>
                    <measurement group_id="O2" value="219.348" spread="123.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="390.671" spread="293.387"/>
                    <measurement group_id="O2" value="238.083" spread="108.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379.246" spread="226.889"/>
                    <measurement group_id="O2" value="235.613" spread="115.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410.292" spread="307.000"/>
                    <measurement group_id="O2" value="258.348" spread="133.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392.813" spread="300.259"/>
                    <measurement group_id="O2" value="251.109" spread="141.894"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410.500" spread="277.375"/>
                    <measurement group_id="O2" value="241.361" spread="123.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380.043" spread="238.041"/>
                    <measurement group_id="O2" value="240.322" spread="131.546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298.445" spread="177.888"/>
                    <measurement group_id="O2" value="285.191" spread="193.643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254.830" spread="134.773"/>
                    <measurement group_id="O2" value="252.930" spread="166.126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244.057" spread="146.336"/>
                    <measurement group_id="O2" value="239.283" spread="138.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Sway to Assess Postural Stability on Day 5 of Period 4 or Day 7 of Period 5 During Part A</title>
        <description>Body Sway test measured the study participant's body movements in a single direction. Body sway was measured by CHCR NeuroCart. Study participants were asked to stand erect and motionless with their eyes closed. The amplitude and direction of any Body Sway was recorded for 1 minute. Participants received either ethanol or placebo on Day 5 of Period 4 or Day 7 of Period 5. Therefore, the results were summarized by treatment.</description>
        <time_frame>Predose, 0.5, 1, 2, 3, 4, 5, 6, 8 and 10 hours on Day 5 of Period 4 or Day 7 of Period 5</time_frame>
        <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation. Here, Number of participants analyzed signifies participants who were evaluable for the assessment and n (number analyzed) signifies participants evaluable at specified time points only.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: PSL + Ethanol (FAS)</title>
            <description>Participants received PSL 200 mg BID oral tablets + Ethanol IV infusion on Day 5 during TP4 in Treatment Sequence A and C and on Day 7 during TP5 in Treatment Sequence B and D. Participants formed the FAS.</description>
          </group>
          <group group_id="O2">
            <title>Part A: PSL + Placebo (FAS)</title>
            <description>Participants received PSL oral tablets 100 mg or 200 mg + Placebo (for ethanol IV infusion) on Day 7 during TP5 in Treatment Sequence A and C and on Day 5 during TP4 in Treatment Sequence B and D. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Sway to Assess Postural Stability on Day 5 of Period 4 or Day 7 of Period 5 During Part A</title>
          <description>Body Sway test measured the study participant's body movements in a single direction. Body sway was measured by CHCR NeuroCart. Study participants were asked to stand erect and motionless with their eyes closed. The amplitude and direction of any Body Sway was recorded for 1 minute. Participants received either ethanol or placebo on Day 5 of Period 4 or Day 7 of Period 5. Therefore, the results were summarized by treatment.</description>
          <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation. Here, Number of participants analyzed signifies participants who were evaluable for the assessment and n (number analyzed) signifies participants evaluable at specified time points only.</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294.843" spread="227.524"/>
                    <measurement group_id="O2" value="317.484" spread="321.623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="746.161" spread="648.448"/>
                    <measurement group_id="O2" value="661.550" spread="943.498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1091.639" spread="965.116"/>
                    <measurement group_id="O2" value="863.255" spread="986.913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1170.452" spread="1118.424"/>
                    <measurement group_id="O2" value="712.391" spread="646.223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="924.800" spread="873.486"/>
                    <measurement group_id="O2" value="499.077" spread="353.668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="903.100" spread="888.205"/>
                    <measurement group_id="O2" value="406.586" spread="279.517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="666.987" spread="735.498"/>
                    <measurement group_id="O2" value="353.905" spread="277.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="489.261" spread="431.766"/>
                    <measurement group_id="O2" value="335.400" spread="256.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="314.713" spread="242.121"/>
                    <measurement group_id="O2" value="277.614" spread="189.464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274.696" spread="180.248"/>
                    <measurement group_id="O2" value="247.100" spread="137.795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Sway to Assess Postural Stability During Part B</title>
        <description>Body Sway test measured the study participant's body movements in a single direction. Body sway was measured by CHCR NeuroCart. Study participants were asked to stand erect and motionless with their eyes closed. The amplitude and direction of any Body Sway was recorded for 1 minute.</description>
        <time_frame>Treatment Period 1: Screening, Day 1 and Day 2</time_frame>
        <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: CBD (FAS)</title>
            <description>Participants received a single oral dose of CBD 10 mg/kg solution, under fasted condition on Day 1 during TP1. Participants formed the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Sway to Assess Postural Stability During Part B</title>
          <description>Body Sway test measured the study participant's body movements in a single direction. Body sway was measured by CHCR NeuroCart. Study participants were asked to stand erect and motionless with their eyes closed. The amplitude and direction of any Body Sway was recorded for 1 minute.</description>
          <population>FAS consisted of all study participants that were randomized, received study medication, and had at least one valid post-baseline primary pharmacodynamic assessment observation.</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Analysis of this outcome measure was not performed because the study was terminated. At that time, Part A had been completed, and 16 study participants had been treated with CBD in Treatment Period 1 of Part B.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events During Part A</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a participant or trial participant that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.</description>
        <time_frame>From Screening up to the Safety Follow-up visit of Part A (up to Day 26)</time_frame>
        <population>Safety Set consisted of all study participants who were randomized and had received at least 1 dose (any amount) of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Pre-treatment (SS)</title>
            <description>Participants with adverse events with a start date prior to the first dose of treatment were summarized in this group for Part A. Participants formed SS.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Placebo (SS)</title>
            <description>Participants received matching placebo (for ethanol IV infusion) on Day 1 during TP1 in Treatment Sequence A and B and on Day 1 during TP2 in Treatment Sequence C and D. Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O3">
            <title>Part A: Ethanol (SS)</title>
            <description>Participants received ethanol 0.6 g/L IV infusion on Day 1 during TP1 in Treatment Sequence A and B and on Day 1 during TP2 in Treatment Sequence C and D. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Part A: PSL (SS)</title>
            <description>Participants received PSL 100 mg or 200 mg oral tablets BID on Day 1 to 4 during TP3 in Treatment Sequence A, B, C and D. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Part A: PSL + Ethanol (SS)</title>
            <description>Participants received PSL 200 mg BID oral tablets + Ethanol IV infusion on Day 5 during TP4 in Treatment Sequence A and C and on Day 7 during TP5 in Treatment Sequence B and D. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Part A: PSL + Placebo (SS)</title>
            <description>Participants received PSL oral tablets 100 mg or 200 mg + Placebo (for ethanol IV infusion) on Day 7 during TP5 in Treatment Sequence A and C and on Day 5 during TP4 in Treatment Sequence B and D. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events During Part A</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a participant or trial participant that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.</description>
          <population>Safety Set consisted of all study participants who were randomized and had received at least 1 dose (any amount) of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events During Part B</title>
        <description>An AE was any untoward medical occurrence in a participant or trial participant that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.</description>
        <time_frame>From Screening up to the Safety Follow-up visit of Part B (up to Day 66)</time_frame>
        <population>Safety Set consisted of all study participants who were randomized and had received at least 1 dose (any amount) of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Pre-treatment (SS)</title>
            <description>Participants with adverse events with a start date prior to the first dose of treatment were summarized in this group for Part B. Participants formed SS.</description>
          </group>
          <group group_id="O2">
            <title>Part B: CBD (SS)</title>
            <description>Participants received a single oral dose of CBD 10 mg/kg solution, under fasted condition on Day 1 during TP1. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events During Part B</title>
          <description>An AE was any untoward medical occurrence in a participant or trial participant that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.</description>
          <population>Safety Set consisted of all study participants who were randomized and had received at least 1 dose (any amount) of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events During Part A</title>
        <description>A serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, is life-threatening, required in patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, is an infection that requires treatment parenteral antibiotics, other important medical events which based on medical or scientific judgement may jeopardize the participants, or may require medical or surgical intervention to prevent any of the above.</description>
        <time_frame>From Screening up to the Safety Follow-up visit of Part A (up to Day 26)</time_frame>
        <population>Safety Set consisted of all study participants who were randomized and had received at least 1 dose (any amount) of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Pre-treatment (SS)</title>
            <description>Participants with adverse events with a start date prior to the first dose of treatment were summarized in this group for Part A. Participants formed SS.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Placebo (SS)</title>
            <description>Participants received matching placebo (for ethanol IV infusion) on Day 1 during TP1 in Treatment Sequence A and B and on Day 1 during TP2 in Treatment Sequence C and D. Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O3">
            <title>Part A: Ethanol (SS)</title>
            <description>Participants received ethanol 0.6 g/L IV infusion on Day 1 during TP1 in Treatment Sequence A and B and on Day 1 during TP2 in Treatment Sequence C and D. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Part A: PSL (SS)</title>
            <description>Participants received PSL 100 mg or 200 mg oral tablets BID on Day 1 to 4 during TP3 in Treatment Sequence A, B, C and D. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Part A: PSL + Ethanol (SS)</title>
            <description>Participants received PSL 200 mg BID oral tablets + Ethanol IV infusion on Day 5 during TP4 in Treatment Sequence A and C and on Day 7 during TP5 in Treatment Sequence B and D. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Part A: PSL + Placebo (SS)</title>
            <description>Participants received PSL oral tablets 100 mg or 200 mg + Placebo (for ethanol IV infusion) on Day 7 during TP5 in Treatment Sequence A and C and on Day 5 during TP4 in Treatment Sequence B and D. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events During Part A</title>
          <description>A serious adverse event (SAE) was any untoward medical occurrence that at any dose resulted in death, is life-threatening, required in patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, is an infection that requires treatment parenteral antibiotics, other important medical events which based on medical or scientific judgement may jeopardize the participants, or may require medical or surgical intervention to prevent any of the above.</description>
          <population>Safety Set consisted of all study participants who were randomized and had received at least 1 dose (any amount) of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events During Part B</title>
        <description>A SAE was any untoward medical occurrence that at any dose resulted in death, is life-threatening, required in patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, is an infection that requires treatment parenteral antibiotics, other important medical events which based on medical or scientific judgement may jeopardize the participants, or may require medical or surgical intervention to prevent any of the above.</description>
        <time_frame>From Screening up to the Safety Follow-up visit of Part B (up to Day 66)</time_frame>
        <population>Safety Set consisted of all study participants who were randomized and had received at least 1 dose (any amount) of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Pre-treatment (SS)</title>
            <description>Participants with adverse events with a start date prior to the first dose of treatment were summarized in this group for Part B. Participants formed SS.</description>
          </group>
          <group group_id="O2">
            <title>Part B: CBD (SS)</title>
            <description>Participants received a single oral dose of CBD 10 mg/kg solution, under fasted condition on Day 1 during TP1. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events During Part B</title>
          <description>A SAE was any untoward medical occurrence that at any dose resulted in death, is life-threatening, required in patient hospitalization or prolongation of existing hospitalization, is a congenital anomaly or birth defect, is an infection that requires treatment parenteral antibiotics, other important medical events which based on medical or scientific judgement may jeopardize the participants, or may require medical or surgical intervention to prevent any of the above.</description>
          <population>Safety Set consisted of all study participants who were randomized and had received at least 1 dose (any amount) of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-related Adverse Events During Part A</title>
        <description>Treatment-related adverse event was an adverse event for which a causal relationship between the product and the occurrence is suspected.</description>
        <time_frame>From Baseline up to Safety Follow-up visit of Part A (up to Day 26)</time_frame>
        <population>Safety Set consisted of all study participants who were randomized and had received at least 1 dose (any amount) of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Placebo (SS)</title>
            <description>Participants received matching placebo (for ethanol IV infusion) on Day 1 during TP1 in Treatment Sequence A and B and on Day 1 during TP2 in Treatment Sequence C and D. Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O2">
            <title>Part A: Ethanol (SS)</title>
            <description>Participants received ethanol 0.6 g/L IV infusion on Day 1 during TP1 in Treatment Sequence A and B and on Day 1 during TP2 in Treatment Sequence C and D. Participants formed the SS.</description>
          </group>
          <group group_id="O3">
            <title>Part A: PSL (SS)</title>
            <description>Participants received PSL 100 mg or 200 mg oral tablets BID on Day 1 to 4 during TP3 in Treatment Sequence A, B, C and D. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Part A: PSL + Ethanol (SS)</title>
            <description>Participants received PSL 200 mg BID oral tablets + Ethanol IV infusion on Day 5 during TP4 in Treatment Sequence A and C and on Day 7 during TP5 in Treatment Sequence B and D. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Part A: PSL + Placebo (SS)</title>
            <description>Participants received PSL oral tablets 100 mg or 200 mg + Placebo (for ethanol IV infusion) on Day 7 during TP5 in Treatment Sequence A and C and on Day 5 during TP4 in Treatment Sequence B and D. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-related Adverse Events During Part A</title>
          <description>Treatment-related adverse event was an adverse event for which a causal relationship between the product and the occurrence is suspected.</description>
          <population>Safety Set consisted of all study participants who were randomized and had received at least 1 dose (any amount) of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-related Adverse Events During Part B</title>
        <description>Treatment-related adverse event was an adverse event for which a causal relationship between the product and the occurrence is suspected.</description>
        <time_frame>From Baseline up to Safety Follow-up visit of Part B (up to Day 66)</time_frame>
        <population>Safety Set consisted of all study participants who were randomized and had received at least 1 dose (any amount) of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: CBD (SS)</title>
            <description>Participants received a single oral dose of CBD 10 mg/kg solution, under fasted condition on Day 1 during TP1. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-related Adverse Events During Part B</title>
          <description>Treatment-related adverse event was an adverse event for which a causal relationship between the product and the occurrence is suspected.</description>
          <population>Safety Set consisted of all study participants who were randomized and had received at least 1 dose (any amount) of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events Leading to Discontinuation of the Study During Part A</title>
        <description>An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.</description>
        <time_frame>From Screening up to Safety Follow-up visit of Part A (up to Day 26)</time_frame>
        <population>Safety Set consisted of all study participants who were randomized and had received at least 1 dose (any amount) of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Pre-treatment (SS)</title>
            <description>Participants with adverse events with a start date prior to the first dose of treatment were summarized in this group for Part A. Participants formed SS.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Placebo (SS)</title>
            <description>Participants received matching placebo (for ethanol IV infusion) on Day 1 during TP1 in Treatment Sequence A and B and on Day 1 during TP2 in Treatment Sequence C and D. Participants formed the Safety Set (SS).</description>
          </group>
          <group group_id="O3">
            <title>Part A: Ethanol (SS)</title>
            <description>Participants received ethanol 0.6 g/L IV infusion on Day 1 during TP1 in Treatment Sequence A and B and on Day 1 during TP2 in Treatment Sequence C and D. Participants formed the SS.</description>
          </group>
          <group group_id="O4">
            <title>Part A: PSL (SS)</title>
            <description>Participants received PSL 100 mg or 200 mg oral tablets BID on Day 1 to 4 during TP3 in Treatment Sequence A, B, C and D. Participants formed the SS.</description>
          </group>
          <group group_id="O5">
            <title>Part A: PSL + Ethanol (SS)</title>
            <description>Participants received PSL 200 mg BID oral tablets + Ethanol IV infusion on Day 5 during TP4 in Treatment Sequence A and C and on Day 7 during TP5 in Treatment Sequence B and D. Participants formed the SS.</description>
          </group>
          <group group_id="O6">
            <title>Part A: PSL + Placebo (SS)</title>
            <description>Participants received PSL oral tablets 100 mg or 200 mg + Placebo (for ethanol IV infusion) on Day 7 during TP5 in Treatment Sequence A and C and on Day 5 during TP4 in Treatment Sequence B and D. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events Leading to Discontinuation of the Study During Part A</title>
          <description>An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.</description>
          <population>Safety Set consisted of all study participants who were randomized and had received at least 1 dose (any amount) of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events Leading to Discontinuation of the Study During Part B</title>
        <description>An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.</description>
        <time_frame>From Screening up to Safety Follow-up visit of Part B (up to Day 66)</time_frame>
        <population>Safety Set consisted of all study participants who were randomized and had received at least 1 dose (any amount) of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Pre-treatment (SS)</title>
            <description>Participants with adverse events with a start date prior to the first dose of treatment were summarized in this group for Part B. Participants formed SS.</description>
          </group>
          <group group_id="O2">
            <title>Part B: CBD (SS)</title>
            <description>Participants received a single oral dose of CBD 10 mg/kg solution, under fasted condition on Day 1 during TP1. Participants formed the SS.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events Leading to Discontinuation of the Study During Part B</title>
          <description>An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.</description>
          <population>Safety Set consisted of all study participants who were randomized and had received at least 1 dose (any amount) of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Screening up to Safety Follow-up visit of Part A (up to Day 26) and of Part B (up to Day 66)</time_frame>
      <desc>An AE was any untoward medical occurrence in a participant or trial participant that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part A: Pre-treatment (SS)</title>
          <description>Participants with adverse events with a start date prior to the first dose of treatment were summarized in this group for Part A. Participants formed SS.</description>
        </group>
        <group group_id="E2">
          <title>Part A: Placebo (SS)</title>
          <description>Participants received matching placebo (for ethanol IV infusion) on Day 1 during TP1 in Treatment Sequence A and B and on Day 1 during TP2 in Treatment Sequence C and D. Participants formed the Safety Set (SS).</description>
        </group>
        <group group_id="E3">
          <title>Part A: Ethanol (SS)</title>
          <description>Participants received ethanol 0.6 g/L IV infusion on Day 1 during TP1 in Treatment Sequence A and B and on Day 1 during TP2 in Treatment Sequence C and D. Participants formed the SS.</description>
        </group>
        <group group_id="E4">
          <title>Part A: PSL (SS)</title>
          <description>Participants received PSL 100 mg or 200 mg oral tablets BID on Day 1 to 4 during TP3 in Treatment Sequence A, B, C and D. Participants formed the SS.</description>
        </group>
        <group group_id="E5">
          <title>Part A: PSL + Ethanol (SS)</title>
          <description>Participants received PSL 200 mg BID oral tablets + Ethanol IV infusion on Day 5 during TP4 in Treatment Sequence A and C and on Day 7 during TP5 in Treatment Sequence B and D. Participants formed the SS.</description>
        </group>
        <group group_id="E6">
          <title>Part A: PSL + Placebo (SS)</title>
          <description>Participants received PSL oral tablets 100 mg or 200 mg + Placebo (for ethanol IV infusion) on Day 7 during TP5 in Treatment Sequence A and C and on Day 5 during TP4 in Treatment Sequence B and D. Participants formed the SS.</description>
        </group>
        <group group_id="E7">
          <title>Part B: Pre-treatment (SS)</title>
          <description>Participants with adverse events with a start date prior to the first dose of treatment were summarized in this group for Part B. Participants formed SS.</description>
        </group>
        <group group_id="E8">
          <title>Part B: CBD (SS)</title>
          <description>Participants received a single oral dose of CBD 10 mg/kg solution, under fasted condition on Day 1 during TP1. Participants formed the SS.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA22.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" events="11" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Feeling Drunk</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Infusion site bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="13" subjects_affected="13" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Catheter site inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anterograde amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E4" events="30" subjects_affected="17" subjects_at_risk="23"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E4" events="13" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E5" events="10" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Slow response to stimuli</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" events="43" subjects_affected="20" subjects_at_risk="23"/>
                <counts group_id="E5" events="23" subjects_affected="15" subjects_at_risk="23"/>
                <counts group_id="E6" events="26" subjects_affected="14" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Sudden onset of sleep</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="33" subjects_affected="15" subjects_at_risk="23"/>
                <counts group_id="E5" events="9" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Bradyphrenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Illusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Negative thoughts</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Yawning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated because the decision was made to terminate the PSL development program in focal-onset seizures on 22 May 2020.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>UCB</name_or_title>
      <organization>Cares</organization>
      <phone>+1844 599 ext 2273</phone>
      <email>UCBCares@ucb.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

